The Journal of Nutritional Biochemistry
Volume 22, Issue 6 , Pages 522-526 , June 2011

Retinol inhibits aromatase activity and expression in vitro

Received 4 August 2009 ,Revised 3 March 2010 ,Accepted 5 April 2010.

References 

  1. Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol. 1999;63:139–188
  2. Formelli F, Meneghini E, Cavadini E, Camerini T, Di Mauro MG, De Palo G, et al. Plasma retinol and prognosis of postmenopausal breast cancer patients. Cancer Epidemiol Biomarkers Prev. 2009;18:42–48
  3. Zhang S, Hunter DJ, Forman MR, Rosner BA, Speizer FE, Colditz GA, et al. Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. J Natl Cancer Inst. 1999;91:547–556
  4. Hunter DJ, Manson JE, Colditz GA, Stampfer MJ, Rosner B, Hennekens CH, et al. prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med. 1993;329:234–240
  5. Tamimi RM, Hankinson SE, Campos H, Spiegelman D, Zhang S, Colditz GA, et al. Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol. 2005;161:153–160
  6. Jeong NH, Song ES, Lee JM, Lee KB, Kim MK, Cheon JE, et al. Plasma carotenoids, retinol and tocopherol levels and the risk of ovarian cancer. Acta Obstet Gynecol Scand. 2009;1–6
  7. Liang D, Lin J, Grossman HB, Ma J, Wei B, Dinney CP, et al. Plasma vitamins E and A and risk of bladder cancer: a case-control analysis. Cancer Causes Control. 2008;19:981–992
  8. Eichholzer M, Stähelin HB, Gey KF, Lüdin E, Bernasconi F. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer. 1996;66:145–150
  9. Sankaranarayanan R, Mathew B. Retinoids as cancer-preventive agents. IARC Sci Publ. 1996;139:47–59
  10. Bonanni B, Lazzeroni M. Retinoids and breast cancer prevention. Recent Results Cancer Res. 2009;181:77–82
  11. Lippman SM, Heyman RA, Kurie JM, Benner SE, Hong WK. Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem Suppl. 1995;22:1–10
  12. De Luca LM, Darwiche N, Celli G, Kosa K, Jones C, Ross S, et al. Vitamin A in epithelial differentiation and skin carcinogenesis. Nutr Rev. 1994;52:S45–S52
  13. Park EY, Dillard A, Williams EA, Wilder ET, Pepper MR, Lane MA. Retinol inhibits the growth of all-trans-retinoic acid-sensitive and all-trans-retinoic acid-resistant colon cancer cells through a retinoic acid receptor-independent mechanism. Cancer Res. 2005;65:9923–9933
  14. Park EY, Wilder ET, Lane MA. Retinol inhibits the invasion of retinoic acid-resistant colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and activity levels. Nutr Cancer. 2007;57:66–67
  15. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA. The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat. 1996;38:85–96
  16. Subbaramaiah K, Cole PA, Dannenberg AJ. Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. Cancer Res. 2002;62:2522–2530
  17. Simpson ER, Michael MD, Agarwal VR, Hinshelwood MM, Bulun SE, Zhao Y. Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J. 1997;11:29–36
  18. Brodie A, Lu Q, Nakamura J. Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol. 1997;61:281–286
  19. Santner SJ, Pauley RJ, Tait L, Kaseta J, Santen RJ. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. Clin Endocrinol Metab. 1997;82:200–208
  20. Miller WR, Forrest AP. Oestradiol synthesis from C19 steroids by human breast cancers. Br J Cancer. 1976;33:116–118
  21. Blankenstein MA, van de Ven J, Maitimu-Smeele I, Donker GH, de Jong PC, Daroszewski J, et al. Intratumoral levels of estrogens in breast cancer. Steroid Biochem Mol Biol. 1999;69:293–297
  22. Sasano H, Harada N. Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocr Rev. 1998;19:593–607
  23. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27–36
  24. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase Inhibitors in the treatment of breast cancer. Endocr Rev. 2005;26:331–345
  25. Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol. 2009;27:53–63
  26. Bradford MMA. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254
  27. Thompson EA, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem. 1974;249:5364–5372
  28. Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc. 1934;56:658–666
  29. Shimodaira K, Fujikawa H, Okura F, Shimizu Y, Saito H, Yanaihara T. Osteoblast cells (MG-63 and HOS) have aromatase and 5 a-reductase activities. Biochem Mol Biol Int. 1996;39:109–116
  30. Zhou D, Clarke P, Wang J, Chen S. Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells. J Biol Chem. 1996;271:15194–15202
  31. Ciolino HP, Wang TT, Sathyamoorthy N. Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide. Br J Cancer. 2000;83:333–337
  32. Andrews WJ, Winnett G, Rehman F, Shanmugasundaram P, Hagen D, Schrey MP. Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. J Steroid Biochem Mol Biol. 2005;94(1-3):159–165
  33. Su B, Mershon MM, Stonerock LA, Curley RW, Brueggemeier RW. 4- Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. J Steroid Biochem Mol Biol. 2008;109:40–46
  34. Hayden LJ, Satre MA. Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells. Breast Cancer Res Treat. 2002;72(2):95–105
  35. Chen AC, Guo X, Derguini F, Gudas LJ. Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol. Cancer Res. 1997;57:4642–4651
  36. Michael MD, Michael LF, Simpson ER. A CRE-like sequence that binds CREB and contributes to cAMP-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene. Mol Cell Endocrinol. 1997;134:147–156
  37. Kijima I, Ye J, Glackin C, Chen S. CCAAT/Enhancer binding protein {delta} up-regulates aromatase promoters I.3/II in breast cancer epithelial cells. Cancer Res. 2008;68:4455–4464
  38. Bahn RS, Worsham A, Speeg KV, Ascoli M, Rabin D. Characterization of steroid production in cultured human choriocarcinoma cells. J Clin Endocrinol Metab. 1981;52:447–450
  39. Thurnham DI, Northrop-Clewes CA. Optimal nutrition: vitamin A and the carotenoids. Proc Nutr Soc. 1999;58:449–457
  40. Dillard AC, Lane MA. Retinol Increases beta-catenin-RXRalpha binding leading to the increased proteasomal degradation of beta-catenin and RXRalpha. Nutr Cancer. 2008;60:97–108
  41. Ueda H, Takenawa T, Millan JC, Gesell MS, Brandes D. The effects of retinoids on proliferative capacities and macromolecular synthesis in human breast cancer MCF-7 cells. Cancer. 1980;46:2203–2209
  42. Fraker LD, Halter SA, Forbes JT. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. Cancer Res. 1984;44:5757–5763

PII: S0955-2863(10)00102-6

doi: 10.1016/j.jnutbio.2010.04.004

The Journal of Nutritional Biochemistry
Volume 22, Issue 6 , Pages 522-526 , June 2011

Article Tools

* Image Usage & Resolution